Volume 52, Issue 1, Pages (July 2007)

Slides:

Advertisements

Similar presentations

TNM staging system for Renal Cell Carcinoma: current status and future perspectives Vincenzo Ficarra Dipartimento di Scienze Oncologiche e Chirurgiche.

Advertisements

Volume 60, Issue 4, Pages (October 2011)

Volume 52, Issue 1, Pages (July 2007)

Volume 155, Issue 3, Pages (March 1996)

Volume 172, Issue 6, Pages (December 2004)

Survival After Single Versus Bilateral Lung Transplantation for High-Risk Patients With Pulmonary Fibrosis Eric S. Weiss, MD, MPH, Jeremiah G. Allen,

Volume 68, Issue 3, Pages (September 2015)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis Maria I. Carlo, Darren R.

Volume 44, Issue 6, Pages (December 2003)

Volume 58, Issue 1, Pages (July 2010)

Volume 55, Issue 2, Pages (February 2009)

Volume 70, Issue 1, Pages (July 2016)

Volume 65, Issue 3, Pages (March 2014)

Testosterone Therapy in Men With Prostate Cancer

Volume 56, Issue 5, Pages (November 2009)

Volume 70, Issue 6, Pages (December 2016)

Renal Cell Carcinoma: Prognostic Factors and Patient Selection

Volume 67, Issue 5, Pages (May 2015)

Volume 51, Issue 1, Pages (January 2007)

Volume 52, Issue 3, Pages (September 2007)

European Urology Oncology

Volume 74, Issue 2, Pages (August 2018)

The Role of Residual Tumor Resection in Patients with Metastatic Renal Cell Carcinoma and Partial Remission following Immunochemotherapy Olaf A. Brinkmann,

Volume 54, Issue 4, Pages (October 2008)

Let the Games Begin (with EAU Approval)

Volume 68, Issue 1, Pages (July 2015)

Volume 60, Issue 4, Pages (October 2011)

Volume 63, Issue 1, Pages (January 2013)

Volume 61, Issue 2, Pages (February 2012)

Volume 66, Issue 2, Pages (August 2014)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 61, Issue 5, Pages (May 2012)

Volume 52, Issue 5, Pages (November 2007)

Volume 68, Issue 1, Pages 5-7 (July 2015)

Volume 62, Issue 3, Pages (September 2012)

Volume 65, Issue 3, Pages (March 2014)

Volume 55, Issue 2, Pages (February 2009)

Volume 58, Issue 4, Pages (October 2010)

Volume 69, Issue 3, Pages (March 2016)

Volume 70, Issue 1, Pages (July 2016)

Reassessing the Current UICC/AJCC TNM Staging for Renal Cell Carcinoma

Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma Francesco Gatto, Kyle A. Blum, Seyedeh Shaghayegh.

International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia Brett Delahunt, John R. Srigley, Lars Egevad,

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 2, Pages (February 2008)

Volume 64, Issue 4, Pages (October 2013)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 52, Issue 2, Pages (August 2007)

Volume 61, Issue 2, Pages (February 2012)

Volume 66, Issue 2, Pages (August 2014)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Volume 59, Issue 1, Pages (January 2011)

Volume 56, Issue 5, Pages (November 2009)

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Volume 53, Issue 1, Pages (January 2008)

Is Simple Enucleation a Minimal Partial Nephrectomy Responding to the EAU Guidelines’ Recommendations? Vincenzo Ficarra, Antonio Galfano, Stefano Cavalleri

Surgical Management of Renal Cell Carcinoma (RCC) with Vena Cava Tumour Thrombus Emanuele Belgrano, Carlo Trombetta, Salvatore Siracusano, Giorgio Carmignani,

Volume 52, Issue 6, Pages (December 2007)

Volume 71, Issue 5, Pages (May 2017)

Volume 54, Issue 4, Pages (October 2008)

Sergio Bracarda European Urology Supplements

Volume 51, Issue 6, Pages (June 2007)

Volume 54, Issue 1, Pages (July 2008)

Volume 52, Issue 4, Pages (October 2007)

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Refining the Nodal Staging for Esophageal Squamous Cell Carcinoma Based on Lymph Node Stations Jun Peng, MD, Wen-Ping Wang, MD, Ting Dong, MD, Jie Cai,

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Volume 64, Issue 4, Pages (October 2003)

Volume 54, Issue 1, Pages (July 2008)

Presentation transcript:

Volume 52, Issue 1, Pages 155-162 (July 2007) Prognostic Relevance of Tumour Size in T3a Renal Cell Carcinoma: A Multicentre Experience John S. Lam, Tobias Klatte, Jean-Jacques Patard, Rakhee H. Goel, François Guillè, Bernard Lobel, Clement-Claude Abbou, Alexandre De La Taille, Jacques Tostain, Luca Cindolo, Vincenzo Altieri, Vincenzo Ficarra, Walter Artibani, Tommaso Prayer-Galetti, Luigi Schips, Richard Zigeuner, Allan J. Pantuck, Robert A. Figlin, Arie S. Belldegrun European Urology Volume 52, Issue 1, Pages 155-162 (July 2007) DOI: 10.1016/j.eururo.2007.01.106 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Kaplan-Meier survival estimates according to the current T stage classification. European Urology 2007 52, 155-162DOI: (10.1016/j.eururo.2007.01.106) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Scatterplot of tumour size versus Martingale residuals for 623 patients with T3a RCC with fat invasion only. The Martingale residual is the difference between the observed and the expected numbers of events for a given patient and demonstrates the expected risk of death from RCC for the patient. Patients above the horizontal line were at increased risk for death from RCC, and those below were at decreased risk for death from RCC compared with the expected risk based on Cox regression analysis. The figure suggests that a tumour size cut-off of 7cm would be appropriate for these patients. European Urology 2007 52, 155-162DOI: (10.1016/j.eururo.2007.01.106) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Kaplan-Meier survival estimates for patients with T2, T3a≤7cm, T3a>7cm, and T3b RCC (Nall Mall). Survival of T2 tended to be better than for T3a≤7cm (p=0.055). Survival of T3a>7cm was similar to T3b (p=0.547). In the interest of clarity, the curves for T3c and T4 RCC are not shown. European Urology 2007 52, 155-162DOI: (10.1016/j.eururo.2007.01.106) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 4 Kaplan-Meier survival estimates for patients with nonmetastatic T2, T3a≤7cm, T3a>7cm, and T3b RCC (N0M0). Survival of T2 was similar to T3a≤7cm (p=0.495) and survival of T3a>7cm was similar to T3b (p=0.918). In the interest of clarity, the curves for T3c and T4 RCC are not shown. European Urology 2007 52, 155-162DOI: (10.1016/j.eururo.2007.01.106) Copyright © 2007 European Association of Urology Terms and Conditions